Agents That Stabilize Mutated von Hippel–Lindau (VHL) Protein: Results of a High-Throughput Screen to Identify Compounds That Modulate VHL Proteostasis
Authors:
Open Access
- 1 June 2012
- journal article
- research article
- Published by Elsevier in SLAS Discovery
- Vol. 17 (5) , 572-580
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Thiazole Antibiotic Thiostrepton Synergize with Bortezomib to Induce Apoptosis in Cancer CellsPLOS ONE, 2011
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Identification of small molecule compounds that inhibit the HIF-1 signaling pathwayMolecular Cancer, 2009
- Androgen Receptor Functional Analyses by High Throughput Imaging: Determination of Ligand, Cell Cycle, and Mutation-Specific EffectsPLOS ONE, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- A retrovirus-based protein complementation assay screen reveals functional AKT1-binding partnersProceedings of the National Academy of Sciences, 2006
- Characterization of a von Hippel Lindau Pathway Involved in Extracellular Matrix Remodeling, Cell Invasion, and AngiogenesisCancer Research, 2006
- Phase II Trial of Bortezomib for Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2004
- A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applicationsNature Biotechnology, 2002